# NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Source: https://onco.cc/trials/nct06342037/  
OnCo record `nct06342037` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tiragolumab, atezolizumab and ipilimumab in triple-negative breast cancer, run by The Netherlands Cancer Institute, now recruiting.

## Summary

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial is a phase 2, randomised interventional study registered as NCT06342037 by The Netherlands Cancer Institute, with a registry enrolment figure of 60 participants, started 2024-06-12 and due to reach its primary completion in 2026-04-01. Interventions recorded: Tiragolumab; Atezolizumab; Ipilimumab. Conditions listed: Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: "* Metastatic or incurable locally advanced triple negative breast cancer with confirmation of Estrogen receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2) negativity (ER \<10%, HER2 IHC 0, 1+ or 2+ with no amplification) on a histological biopsy of a metastatic lesion". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TONIC-3
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06342037
- Phase: 2
- Setting: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
- Sponsor: The Netherlands Cancer Institute
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06342037: https://clinicaltrials.gov/study/NCT06342037

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06342037.json